The latest news for pharma industry insiders.

Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.

The latest news for pharma industry insiders.

With the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.

A C-suite Q&A with Cristina Ortega Duran, President of Evinova.

Data from the Phase II/III DEVOTE study demonstrated that Spinraza showed significant motor function improvements at six months in infants with spinal muscular atrophy.

Results from the FINE-HEART pooled analysis of three Phase III clinical trials highlighted the potential of finerenone in treating high-risk cardiovascular patients.

The latest news for pharma industry insiders.

The Dandelion Health CEO discusses the collection and analysis of data in the digital world.

The company partnered with Marius Pharmaceuticals to offer access to Kyzatrex.

The “Do It For You & Them” campaign focuses on the impact that virus has on day-to-day lives.

Results of the RESTORE study revealed that 94% of participants preferred Lumryz over twice nightly oxybate treatments for narcolepsy.

Results from the Phase III EXPLORER-LTE study found that Camzyos maintained effectiveness in treating symptomatic obstructive hypertrophic cardiomyopathy after 3.5 years of treatment.

The latest news for pharma industry insiders.

As the second half of 2024 begins, an industry expert discusses how mergers and acquisitions are trending in the pharma industry.

The insurance company is offering the guidance in response to continued popularity of the drugs which are commonly used for weight-loss management.

Perspective Therapeutics’ CEO explains how this method can be used to determine how to target cancer cells without damaging other organs.

Submission is supported by results from the Phase III Vivacity-MG3 study, which demonstrated that nipocalimab, combined with standard care, significantly improved outcomes for patients with antibody-positive generalized myasthenia gravis.

The product line includes vaccines, monoclonal antibodies, and antigens.

Pharmaceutical companies are seeing the benefits of being able to outsource entire functions through functional service providers.

Strategies that can help maintain and grow your market share. Plus how to adapt to new competitive pressures and evolving customer needs.

The latest news for pharma industry insiders.

Submission of a New Drug Application for mirdametinib included data from the Phase IIb ReNeu trial, which evaluated patients with NF1-associated plexiform neurofibromas causing significant morbidity.

Results of the INTEGUMENT-OLE study found that the roflumilast cream not only maintained but improved its efficacy over time treating children from two to five years of age with mild to moderate atopic dermatitis.

Due to increasing complexity of modern technology, FDA should consider updating its 510(k) process.